JPMorgan Reinstates Stoke Therapeutics (STOK) at Neutral
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Price: $31.31 -5.03%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Neutral rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.
Shares of Stoke Therapeutics closed at $4.22 yesterday.
You May Also Be Interested In
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral
- JPMorgan Assumes Bravura Solutions Ltd (BVS:AU) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
